Control of ventricular rate in permanent atrial fibrillation: cardio­protec­tion and tissue hemodynamics

Objective To evaluate myocardial injury and tissue hemodynamics in elderly patients with permanent atrial fibrillation (AF) based on the achieved range of ventricular contraction rate (VCR).

Materials and Methods This prospective, randomized, blind study included 75 patients aged ≥60 with permanent AF. All patients were prescribed bisoprolol as a VCR-reducing therapy. Patients were randomized to two groups according to the permuted-block design based on the range of resting VCR goal: group 1, 60–79 bpm (n=38) and group 2, 80–100 bpm (n=37). All patients also received perindopril and apixaban. Troponin I concentration was measured using the high-sensitivity assay (hsTn); parameters of tissue hemodynamics, including the mean blood flow velocity (Vm) and pulsatility index (PI), were measured using high-frequency ultrasound doppler flowmetry; echocardiographic indexes of left heart remodeling were recorded at baseline and after 6 month of VCR monitoring.

Results Mean age of patients was 74±7 years. Medians [25th percentile; 75th percentile] of baseline hsTn concentrations were 10.2 [5.25; 21.2] ng / l in group 1 and 10.3 [5.4; 20.4] ng / ml in group 2 (p=0.91). 89.5 % of patients in group 1 and 100 % of patients in group 2 achieved the VCR range goal. At 6 month, resting VCRs were 70±4 bpm in group 1 (n=34) and 88±5 bpm in group 2 (n=37) (p1, p2<0.001). According to echocardiographic data significant progression of myocardial remodeling was not observed. Concentrations of hsTn significantly decreased in both groups but the decrease was more pronounced in group 1, to 8.0 [4.13; 17.23; p1<0.001] ng / l vs. 9.2 [4.8, 17.5] ng / l in group 2 (р1, p2<0.001). A weak direct correlation was found between the VCR decrease and hsTn concentration (rs=0.44; p=0.009 in group 1, and rs=0.41; p=0.01 in group 2); regression coefficient was 0.78 at 95 % confidence interval (CI), from 0.21 to 1.3 (p=0.009) in group 1, and 0.14 at 95 % CI, from 0.04 to 0.24 (p=0.007) in group 2. Vm values were increased to 2.93±0.10 (p<0.001) and 3.21±0.09 cm / sec (p<0.001) and PIs were decreased to 1.42±0.03 conv. units (p<0.01) and to 1.34±0.02 conv. units (p<0.001) in groups 1 and 2, respectively.

Conclusion The treatment aimed at VCR control in patients older than 60 with permanent AF was associated with a positive dynamics of myocardial injury (hsTn) and tissue hemodynamics indexes (Vm и РI). This indicates a possibility for using these indexes for further improvement of managing such patients.

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78. DOI: 10.1093/europace/euw295

2. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. The New England Journal of Medicine. 2010;362(15):1363–73. DOI: 10.1056/NEJMoa1001337

3. Groenveld HF, Crijns HJGM, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JGP et al. The Effect of Rate Control on Quality of Life in Patients With Permanent Atrial Fibrillation. Journal of the American College of Cardiology. 2011;58(17):1795–803. DOI: 10.1016/j.jacc.2011.06.055

4. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8(11):935–42. DOI: 10.1093/europace/eul106

5. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2019;74(1):104–32. DOI: 10.1016/j.jacc.2019.01.011

6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

7. Li S-J, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M et al. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. Circulation: Heart Failure. 2015;8(5):871–9. DOI: 10.1161/CIRCHEARTFAILURE.115.002285

8. Hagens VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAte Control versus Electrical cardioversion (RACE) study. American Heart Journal. 2005;149(6):1106–11. DOI: 10.1016/j.ahj.2004.11.030

9. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. New England Journal of Medicine. 2002;347(23):1834–40. DOI: 10.1056/NEJMoa021375

10. Bokeria L.A., Bokeria O.L., Bazarsadaeva T.S., Salia N.T., Donakanyan S.A., Biniashvili M.B. et al. Characteristics of NO-dependent autoregulation of tissual blood flow at idiopathic atrial fibrillation. Annals of Arrhythmology. 2013;10(2):94–101. [Russian: Бокерия Л.А., Бокерия О.Л., Базарсадаева Т.С., Салия Н.Т., Донаканян С.А., Биниашвили М.Б. и др. Характеристика NO-зависимой ауторегуляции тканевого кровотока при идиопатической фибрилляции предсердий. Анналы аритмологии. 2013;10(2):94-101]

11. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425

12. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal – Cardiovascular Imaging. 2015;16(3):233–71. DOI: 10.1093/ehjci/jev014

13. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2016;29(4):277–314. DOI: 10.1016/j.echo.2016.01.011

14. Belenkov Yu.N., Mareev V.Yu. Principles of rational treatment of chronic heart failure. -M.: Media Medika;2000. - 266 p. [Russian: Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения хронической сердечной недостаточности. -М.: Медиа Медика; 2000. - 266с]

15. Orekhova LY, Barmasheva AA. Doppler flowmetry as a tool of predictive, preventive and personalised dentistry. EPMA Journal. 2013;4(1):21. DOI: 10.1186/1878-5085-4-21

16. Petrishchev N.N., Menshutina M.A., Vlasov T.D., Vasina E.Yu., Girina M.B., Didur M.D. Complex of diagnostics of vascular endothelial dysfunction. Russia. Patent RU 47202. 2005. Zayavka 2005110746/22. . [Russian: Петрищев Н.Н., Меншутина М.А., Власов Т.Д., Васина Е.Ю., Гирина М.Б., Дидур М.Д. Комплекс диагностики дисфункции эндотелия сосудов. Патент России. Номер патента RU 47202. 2005. Номер заявки 2005110746/22]

17. Bagnenko S.S., Decan V.S., Ivanova L.A., Ivanova L.I., Ischenko B.I., Kovalchuk G.V. et al. Ultrasound Diagnostics. A Guide for Physicians. -SPb: Foliant;2009. - 800 p. [Russian: Багненко С.С., Декан В.С., Иванова Л.А., Иванова Л.И., Ищенко Б.И., Ковальчук Г.В. и др. Ультразвуковая диагностика. Руководство для врачей. - СПб: Фолиант; 2009. - 800с]. ISBN 978-5-93929-185-9

18. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–164. [Russian: Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН–РКО–РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-164]. DOI: 10.18087/cardio.2475

19. Horjen AW, Ulimoen SR, Enger S, Berge T, Ihle-Hansen H, Norseth J et al. Impact of atrial fibrillation on levels of high-sensitivity troponin I in a 75-year-old population. Scandinavian Journal of Clinical and Laboratory Investigation. 2015;75(4):308–13. DOI: 10.3109/00365513.2015.1011224

20. Webb IG, Yam ST, Cooke R, Aitken A, Larsen PD, Harding SA. Elevated Baseline Cardiac Troponin Levels in the Elderly – Another Variable to Consider? Heart, Lung and Circulation. 2015;24(2):142–8. DOI: 10.1016/j.hlc.2014.07.071

21. Hussein AA, Bartz TM, Gottdiener JS, Sotoodehnia N, Heckbert SR, Lloyd-Jones D et al. Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. Heart Rhythm. 2015;12(5):879–85. DOI: 10.1016/j.hrthm.2015.01.020

22. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014;100(15):1193–200. DOI: 10.1136/heartjnl-2013-304872

23. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D et al. High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2014;129(6):625–34. DOI: 10.1161/CIRCULATIONAHA.113.006286

24. Horjen AW, Ulimoen SR, Enger S, Norseth J, Seljeflot I, Arnesen H et al. Troponin I levels in permanent atrial fibrillation – impact of rate control and exercise testing. BMC Cardiovascular Disorders. 2016;16(1):79. DOI: 10.1186/s12872-016-0255-x

25. Hoshide S, Fukutomi M, Eguchi K, Watanabe T, Kabutoya T, Kario K. Change in High-Sensitive Cardiac Troponin T on Hypertensive Treatment. Clinical and Experimental Hypertension. 2013;35(1):40–4. DOI: 10.3109/10641963.2012.689044

26. Wolke C, Bukowska A, Goette A, Lendeckel U. Redox control of cardiac remodeling in atrial fibrillation. Biochimica et Biophysica Acta (BBA) - General Subjects. 2015;1850(8):1555–65. DOI: 10.1016/j.bbagen.2014.12.012

27. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008;10(2):238–41. DOI: 10.1093/europace/eum283

28. Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. European Heart Journal. 2009;30(11):1411–20. DOI: 10.1093/eurheartj/ehp046

29. Fudim M, Ambrosy AP, Sun J, Anstrom KJ, Bart BA, Butler J et al. High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. Journal of the American Heart Association. 2018;7(24):e010364. DOI: 10.1161/JAHA.118.010364

30. Gohar A, Chong JPC, Liew OW, den Ruijter H, de Kleijn DPV, Sim D et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction: Cardiac troponin assays in prognosis. European Journal of Heart Failure. 2017;19(12):1638–47. DOI: 10.1002/ejhf.911

31. Peacock WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS et al. Cardiac Troponin and Outcome in Acute Heart Failure. New England Journal of Medicine. 2008;358(20):2117–26. DOI: 10.1056/NEJMoa0706824

32. Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study: Troponin in Acute Heart Failure. European Journal of Heart Failure. 2015;17(12):1262–70. DOI: 10.1002/ejhf.341

33. Yousufuddin M, Abdalrhim AD, Wang Z, Murad MH. Cardiac troponin in patients hospitalized with acute decompensated heart failure: A systematic review and meta-analysis: cTn in Patients Hospitalized with ADHF. Journal of Hospital Medicine. 2016;11(6):446–54. DOI: 10.1002/jhm.2558

34. Aimo A, Januzzi JL, Vergaro G, Ripoli A, Latini R, Masson S et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation. 2018;137(3):286–97. DOI: 10.1161/CIRCULATIONAHA.117.031560

35. Scarsoglio S, Saglietto A, Anselmino M, Gaita F, Ridolfi L. Alteration of cerebrovascular haemodynamic patterns due to atrial fibrillation: an in silico investigation. Journal of The Royal Society Interface. 2017;14(129):20170180. DOI: 10.1098/rsif.2017.0180